Maegim한국어

폴라리스AI파마

041910KOSDAQSector: Pharma & Biotech
₩5,350▼ 4.12%Market cap ₩71.1BAs of Jul 21, 2026 close · updated once daily
A
Grade A68.1 ptsTop 15% of 2,523 stocks
Financial strength
66.2
Growth momentum
48.4
Price attractiveness
84.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

66.2
How much debt does it carry relative to equity?
Debt-to-equity ratio
44.1%
✓ Above median · Top 41.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
261.5%
✓ Above median · Top 37.6% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
5.7%
✓ Above median · Top 27% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
4.5%
✓ Above median · Top 29.1% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

48.4
How much did revenue grow in a year?
Revenue growth (YoY)
-6.8%
✗ Below median · Top 77.4% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-3.6%
✗ Below median · Top 75% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
1712.2%
✓ Above median · Top 1.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
0.9%
✗ Below median · Top 53% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

84.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
11.5x
✓ Above median · Top 17.7% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.52x
✓ Above median · Top 13.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15